Mapping the Clinicopathologic and Molecular Genetic Evolution of Cutaneous T-Cell Lymphoma Peter Louis1, Michael Berger PhD1, Rose Brannon PhD1, Helen.

Slides:



Advertisements
Similar presentations
Amy Y-Y Chen, MD Andrew Chen, MD
Advertisements

Making Sense of Novel Prognostics: NOTCH1, SF3B1 Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute October 24, 2014.
Research Techniques Made Simple: T-Cell Receptor Gene Rearrangement
Multitarget Stool DNA Testing for Colorectal-Cancer Screening NEJM April 3, 2014 Vol 3 Imperiale, T.F. et al Presented by Melissa Spera, MD.
Mycosis Fungoides and Sezary Syndrome
By the end of this session you should know:
Primary Cutaneous Lymphoma Heterogeneous group of T and B-cell lymphomas variation in –clinical presentation –histology –immunophenotype –prognosis Incidence.
Procedures used by CHTN
Calciphylaxis Induced Ulcerations. John M. Lavelle, 1 DO; Paul Liguori MD 2 1. Boston University Medical Center, Rehabilitation Department 2. Whittier.
LYMPHOMA.
Dermatology Aspects of Cutaneous T-cell Lymphoma
GASTRIC LYMPHOMAS Aswad H. Al.Obeidy FICMS, FICMS GE&Hep Kirkuk General Hospital.
Hairy leukoplakia Distinctive oral lesion Seen in immunocompromised patients 80% of patients with hairy leukoplakia have HIV infection.
STATEMENTS 2008 on Head and Neck Cancer Stephane TEMAM, M.D. PhD. Department of Head and Neck Surgery Mucosal Melanoma.
Pathology Reports Nicole Draper, MD.
Chapter 6 Cancer. Frequency and Significance Cancer is the 2 nd leading cause of death in the United States Obviously, the term cancer covers many types.
T Cell Low Grade Lymphomas. General Principles General Principles  Usually Primary Skin lymphomas  Typically indolent Course  Conservative management.
CSv2 for the Hematopoietic Neoplasms 1. 2 This includes five schemas …. Hematopoietic, Reticuloendothelial, Immunopro-liferative and Myeloproliferative.
HANDOUT 3 RARITIES.
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Quantifying Skin Disease Burden in Mycosis Fungoides–Type.
Asymptomatic lymphadenopathy Mediastinal mass Systemic symptoms Fever, Pruritus Other nonspecific symptoms and paraneoplastic syndromes Intra-abdominal.
Cellular origin of lymphoma
Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;
The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinical findings, histology, and immunohistochemistry  Moritz.
“Malignant skin tumors”
© The Author(s) Published by Science and Education Publishing.
An unusual type of primary breast lymphoma
Cellular origin of lymphoma
Site(s) of Involvement Serum IgG4 Level (mg/dL) Treatment with Steroid
Age and Racial/Ethnic Disparities in the Diagnosis of Breast Cancer in an Urban Population Joanne K. Fagan PhD, Denise Fyffe, PhD, Nadine Jenkins, CTR,
CASE SUBMISSION 2016 EAHP BM Workshop
SD Walter MD1, T Mahten MD2, JW Harbour MD1,3
The Carroll A. Campbell, Jr. Neuropathology Laboratory (Brain Bank)
Chronic immune activation in HIV associated Non Hodgkin lymphoma and the effect of antiretroviral therapy Brian Flepisi University of the Western Cape.
PRIMARY CUTANEOUS γδ T-CELL LYMPHOMA:REPORT OF A RARE ENTITY
Prognosis of younger patients in non-small cell lung cancer
A case series presentation
MLAB Hematology Keri Brophy-Martinez
CANCER.
DNA Extraction of Lung Cancer Samples for Advanced Diagnostic Testing
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Clonal evolution of resistance to sequential ALK inhibitor therapy.
Initial Diagnosis of MF-CTCL: A Collaborative Approach
Volume 1, Issue 4, Pages (July 2015)
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for.
Focus on lymphomas Cancer Cell
Steven H Itzkowitz, Noam Harpaz  Gastroenterology 
UHRF1 is regulated by miR-9 in colorectal cancer
Khalid Al Hawsawi Dermatology Consultant
Ming Yang Bi, AB, Jonathan L. Curry, MD, Angela M
European Urology Oncology
WHO-EORTC classification for cutaneous lymphomas
The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinical findings, histology, and immunohistochemistry  Moritz.
Fluorescence In Situ Hybridization
Volume 2, Issue 1, Pages (January 2016)
Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma
Caught in transformation
Characterizing the Histologic Morphology of Liver Cancer: Creating a Formalin Fixed Paraffin Embedded Tissue Repository Tamar Taddei, MD.
AMR Seminar Symposium Split, Croatia Case #63
Volume 2, Issue 1, Pages (January 2016)
Absence of Microsatellite Instability and Lack of Evidence for Subclone Diversification in the Pathogenesis and Progression of Mycosis Fungoides  Chalid.
Dr Yve Zhang (Consultant, Cellular Pathology)
Hong Wu, Mitchell Smith, Michael M
A Rare but Revealing Sign: Necrolytic Migratory Erythema
Cutaneous T-Cell Lymphoma: Disease, Diagnosis, and Therapy
Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR by Duncan Murray, Jack Luke McMurray,
Expression of the CD4+ Cell-Specific Chemoattractant Interleukin-16 in Mycosis Fungoides  Volker Blaschke, Kristian Reich, Michael Letschert, Florian.
Figure 1. Radiographic and gross pathologic measurements of ‘tumor mass’ include areas of immune-mediated tumor ... Figure 1. Radiographic and gross pathologic.
Marked differences in the density, composition and microanatomical distribution of infiltrating immune cells in cutaneous squamous cell carcinoma and the.
CD4/CD8 double-negative early-stage mycosis fungoides associated with primary cutaneous follicular center lymphoma  Jeong Hee Cho-Vega, MD, PhD, Jaime.
Presentation transcript:

Mapping the Clinicopathologic and Molecular Genetic Evolution of Cutaneous T-Cell Lymphoma Peter Louis1, Michael Berger PhD1, Rose Brannon PhD1, Helen Won1, Christiane Querfeld MD PHD2, Steven Horwitz MD2, Patricia L. Myskowski MD2, Melissa Pulitzer MD1 Department of Pathology1 and Department of Medicine2 Memorial Sloan Kettering Cancer Center

Purpose The aim of this study is to determine if there is molecular genetic heterogeneity within chronologically and spatially distinct lesions of patients with Cutaneous T-Cell Lymphoma (CTCL), and to compare any such changes with clinical and pathologic characteristics.

Background CTCL is a rare but potentially lethal malignancy of skin-homing T-lymphocytes. The annual incidence of CTCL in the United States is between 4-8 per 1,000,000 persons Mycosis Fungoides (MF) is the most prevalent subset of CTCL, accounting for over 50% of cases While the overall mortality of MF is low, at approximately 100 deaths per year, patients with tumor stage disease have a 5-year disease specific survival of 30% Currently, there is no curative therapy for patients with advanced stage MF

Background Little is known in specific cancers, if genetic and epigenetic changes are conserved throughout the chronologic or spatial progression of a tumor Recent data suggests that mutational intratumoral heterogeneity may be greater than expected In this context, our objective is to evaluate sequential and spatially distinct specimens from select MF patients, in order to evaluate the molecular evolution of their tumors, and to relate genetic findings with clinical and pathologic features.

Background Patch stage lesions are typically thin, non-infiltrated, pink, and slightly scaly. The sites of predilections are the sun-protected areas such as the buttocks. Plaque stage lesions are generally flat, indurated and elevated above the skin surface. Any area of the body surface may be involved. Tumor stage MF most commonly presents as nodules. Erythrodermic MF presents as widespread erythema. Lymph node and visceral involvement, as well as large cell transformation, usually occur in the late stage of the disease.

Study Design We identified patients with a clinicopathologic diagnosis of advanced stage MF, confirmed by review of clinical records, and by examination of pathology slides and reports Seven patients were selected, who had in-house normal control tissue and sequential and/or synchronous biopsies of MF in skin and/or lymph node tissue. Clinical and pathologic data, including demographics, survival, histologic, immunophenotypic, and molecular findings were recorded. Formalin-fixed paraffin embedded (FFPE) tumor tissues and normal controls were obtained from the MSKCC pathology archive Genomic DNA was extracted from FFPE tissue sections using standard methods. Samples were analyzed for the presence of somatic point mutations, small indels and copy number alterations using publicly available algorithms

Table 1 . Patient and Biopsy Characteristics Case# Site of 1st Biopsy Stage at 1st Biopsy Clinical presentation at 1st Biopsy Age at 1st Biopsy Site of 2nd Biopsy Stage at 2nd Biopsy Clinical presentation at 2nd Biopsy Age at 2nd Biopsy Time Elapsed between Biopsies (Months) 1 Left cheek IIB Scaly patches, erythematous nodules, multiple violaceous tumors 59 Right upper abdomen Poikilodermatous patch, large erythematous plaques, and crusted ulcerations, extensive nodules on foot 60 6 2 Right abdomen IB Hypopigmented patches 66 Axillary lymph node IVA2 Hypopigmented patches, diffusely excoriated, thickened with scale 74 94 3 Left axilla Large ulcerated nodular tumors with necrosis Right axilla, soft tissue Multiple erythematous, weeping tumors 4 Left nasal bridge Hyperpigmented patches, eroded nodule 62 5 Right lower leg Multiple patches and thick plaques 73 Right dorsum tongue Multiple patches and plaques 75 18 Right lateral low back Multiple large erythematous patches and plaques Right middle low back 7 Left leg Diffuse erythema over face, erythrematous plaques 57 Left lower back Multiple slightly erythematous plaques and nodules 23 Age, Stage and Survival correlate with time at diagnosis. Anatomic site refers to skin, unless otherwise specified. "1st biopsy" indicates first biopsy analyzed for this study. "2nd biopsy" indicates second biopsy analyzed for this study. AJCC TNM staging used is as follows: IA correlates to patch or plaque covering less than 10 percent of skin; IB correlates to patch or plaque covering greater than 10 percent of skin; IIB correlates to tumor stage disease; IVA2 correlates to lymph node effacement by MF H Hispanic; NH Non-Hispanic; W White

A B C D Figure 1. A. Case 1 upon presentation with tumor stage MF/LCT. B. Close-up photo of the region biopsied. C. 6 months later, tumors on the abdomen. D. Close-up view of the area biopsied

A B Figure 2. A, B Low power, punch biopsies of case, 1 diffuse sheets of tumor.

A B C Figure 3. A. Case 2, biopsy of plaque stage disease. B, C. Low and high power photomicrographs of effaced lymph node and transformed disease.

Same Clone Present in Both Biopsies Table 2. Pathologic Characteristics 1st Biopsy 2nd Biopsy   Case # CD3 CD4 (%) CD8 (%) CD4:CD8 CD7 Clonal Beta TCR Clonal Gamma TCR TCR Beta TCR Gamma Same Clone Present in Both Biopsies 1 + 99 25:1 preserved ND 70 5 15:1 loss 2 80 10 8:1 Yes 3 No** 4 20 4:1 90 10:1 95 20:1 6 7 ND = No Data **Necrosis

Table 3. Summary of Data Patient Characteristics Male:Female 4:3   Male:Female 4:3 Median time from first sign to diagnosis (months; range) 18.5 (1.5 - 158) Median age at diagnosis (years; range) 60 (51 - 75) Median time to death from diagnosis (months; range) 43 (8 - 131) Median age at 1st biopsy (years; range) 62 (57 -75) Median age at 2nd biopsy (years; range) 62 (59 -75) Cases with large cell transformation 5 Tumor characteristics Number of skin biopsies (tumor/plaque) 11 (8/3) Skin lesions with large cell transformation (tumor/plaque) 7 (7/0) Number with tumor in lymph node 1* Patients with folliculotropism 5/6 Patients with follicular mucin 1/6 Tumor in other location 2* Median interval between biopsies (months, range) 6 (0 - 94) *A 2nd might have been node, but unclear, so placed in "other location"

Conclusions/Future Directions Evolution of CTCL in our patients was characterized in part by clinical, histologic, and immunophenotypic changes, however, these changes are not consistent or predictable We await the findings of our targeted mutational analysis to see if conservation or evolution of cancer-related mutations in CTCL better characterize progression of disease.

References Zackheim, H. S. (2005). Cutaneous T-cell lymphoma : Mycosis Fungoides and Sézary syndrome. Boca Raton, Fla., CRC Press. Quaglino P, Pimpinelli N, Berti E, et al. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer. Jun 6 2012.